Assessing the Impact of AEDs: What Constitutes Clinical Meaningful Effect for Dravet Syndrome

Released On
August 25, 2020

Expires On
July 31, 2021

Media Type

Completion Time
60 minutes

Neurology, Pediatrics

Dravet Syndrome

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.


This activity is supported by an educational grant from Zogenix, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact hour(s)
  • Pharmacist — 1.0 Contact hour(s) (0.10 CEUs)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The educational design of this activity addresses the needs of neurologists, pediatric neurologists, pediatricians and other health care professionals (including physicians, physicians-in-training, nurses, physician assistants, nurse practitioners, pharmacists, etc.) involved and/or interested in the management of patients with severe forms of pediatric intractable epilepsy.

Statement of Need/Program Overview

For years, a 50% or greater reduction in seizure frequency has been the benchmark to assess the efficacy of anti-epileptic drugs (AEDs) in the treatment of Dravet syndrome. However, there is some concern that the use of this endpoint alone does not accurately measure outcomes that are clinically meaningful to patients. Many care visits are spent discussing non-seizure consequences of epilepsy syndromes, such as cognitive, psychological, and social issues that negatively affect patients and their families. Join Dr. Joseph Sullivan and Dr. Orrin Devinsky as they discuss the need for a validated, reliable, and usable instrument to measure non-seizure outcomes in patients. These experts will review the Clinical Global Impression of Improvement (CGI-I) as a potential efficacy measure, explore the use of disease-specific rating scales, and encourage the consideration of comorbidities that can impact treatment decisions and patent QoL as much as or more than seizure control.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Examine seizure and non-seizure measures to evaluate treatment success with antiepileptic drugs
  • Identify strategies to critically appraise clinically meaningful measures in collaboration with families affected by Dravet syndrome


Joseph Sullivan, MD

Director, UCSF Pediatric Epilepsy Center
Co-director, PISCES Longitudinal Integrated Clerkship
Professor of Neurology & Pediatrics,
UCSF Benioff Children's Hospital


Orrin Devinsky, MD

Professor, Department of Neurology
NYU Grossman School of Medicine

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-089-H01-P)
This is a knowledge-based activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Disclosure of Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Joseph Sullivan, MD

  • Consultant/Independent Contractor: Epygenix, Encoded
  • Grant/Research Support: Zogenix, Stoke, Marinus, Biopharm
  • Advisory Board: Invitae
  • Stock Shareholder: Epygenix

Orrin Devinsky, MD

  • Consultant/Independent Contractor: Tevard Biosciences, Script Biosciences, Regel Biosciences
  • Advisory Board: Tevard Biosciences, Script Biosciences, Regel Biosciences
  • Stock Shareholder: Tevard Biosciences, Script Biosciences, Regel Biosciences

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Ashley Marostica, RN, MSN: Nothing to disclose
  • Lindsay Borvansky: Nothing to disclose
  • Andrea Funk: Nothing to disclose
  • Liddy Knight: Nothing to disclose
  • Ashley Cann: Nothing to disclose
  • Carole Drexel: Nothing to disclose
  • Elizabeth del Nido: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting with the subject line “Data Request”

You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: